Dr. Milan Obradovic received a DVM in 2007 from the School of Veterinary Medicine, the University of Belgrade, an MSc from the Faculty of Pharmacy, the University of Belgarde in 2013, and a PhD from the University of Saskatchewan in 2019. From 2019 to 2020 Dr. Obradovic worked at Dr. Gottschalk and Dr. Segura’s laboratory at the University of Montreal, where he was a project manager and postdoctoral fellow involved in three international vaccine projects to develop new vaccines against Streptococcus suis in pigs funded by the International Development Research Center.
In 2020 Dr. Obradovic joined the Charles River Laboratories as a Research Scientist and Study Director, engaged in the development and testing of diverse types of pharmaceutical products, such as DNA plasmid vaccines, bacterial vaccines, anti-cancer vaccines, adjuvants, adenovirus vector vaccines, and antibodies and other immunotherapeutic. He joined VIDO as a Head of Client Services, responsible for contract research studies in 2022.
Dr. Obradovic's research background lies in the planning and managing of vaccine and immunotherapeutic preclinical studies following Good Laboratory Principles (GLP), vaccine efficacy studies, and biologics production following Good Manufacturing Principles. Dr. Obradovic received extensive training in different animal models (non-human primates, rabbits, mini-pigs, rats, mice, hamsters, ferrets) and diverse studies, such as discovery, efficacy, toxicology, and safety studies. He collaborated with various clients, from major pharmaceutical companies to small and medium-sized vaccine development companies, from major Universities to Scientific Institutes and funding agencies.